Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Dermatology

Treatment Strategy: From Creams to Targeted Biologics

At a Glance

Psoriasis treatment aims to stop systemic inflammation and achieve clear skin. Mild cases are typically treated with topical creams, while moderate-to-severe cases may require systemic oral medications or highly targeted biologic injections like IL-17 or IL-23 inhibitors.

Treating psoriasis has moved far beyond simply “managing a rash.” Today, the medical community views treatment as a way to shut down systemic inflammation and restore your quality of life. Whether you have a few spots or widespread disease, there is a clear, evidence-based progression of care designed to get your skin clear and keep it that way [1][2].

Step 1: Mild Psoriasis (Topical Care)

If your psoriasis affects a small portion of your body—typically less than 3%—the first line of defense is topical therapy (medications applied directly to the skin).

  • Combination Creams: The “gold standard” for mild cases is often a fixed combination of a steroid (betamethasone) and a vitamin D analogue (calcipotriol) [3][4]. Warning: Do not stop steroid creams abruptly without a doctor’s guidance, as this can cause a “rebound” flare of your symptoms.
  • Non-Steroidal Options: New options like tapinarof cream provide effective relief without the long-term thinning of the skin sometimes associated with steroids [5].
  • Phototherapy: If creams aren’t enough, narrowband UVB (NBUVB) light therapy uses specific wavelengths of light to slow down skin cell growth [6][7].

Step 2: Moderate-to-Severe Psoriasis (Systemic Care)

When psoriasis covers more than 10% of the body, or if it significantly impacts “high-stakes” areas like the face, hands, or genitals, doctors move to systemic treatments that work throughout the entire body [1].

Oral Systemics

  • Methotrexate: A long-standing, effective oral medication that helps calm an overactive immune system [8]. Note: It requires regular blood work to monitor for potential liver or blood toxicity, and strict pregnancy avoidance is necessary.
  • Apremilast: A newer pill (a PDE4 inhibitor) that is often used for patients who want to avoid injections or who have specific comorbidities like metabolic syndrome [9][10].
  • TYK2 and JAK Inhibitors: Medications like deucravacitinib (a TYK2 inhibitor) are newer oral options that target specific immune pathways and are approved for broader use, while older JAK inhibitors are typically reserved for refractory cases [11].

Step 3: The Biologic Paradigm Shift

In recent years, the treatment of moderate-to-severe psoriasis has shifted toward biologics. These are highly targeted injections that “intercept” the specific inflammatory signals (cytokines) that drive the disease [12].

Target Common Examples Key Benefit
IL-17 Inhibitors Secukinumab, Ixekizumab, Bimekizumab Speed: These typically have the fastest onset of action and can often achieve 100% skin clearance (PASI 100) within weeks [13][14].
IL-23 Inhibitors Risankizumab, Guselkumab, Tildrakizumab Durability: While they may take a bit longer to reach full effect, they are known for staying effective for a long time and often require fewer injections (sometimes only once every 3 months) [15][16].
TNF-alpha Inhibitors Adalimumab, Etanercept Broad Use: These were the first biologics and are still widely used, especially if you also have psoriatic arthritis or inflammatory bowel disease [17].

Understanding the Risks and Trade-offs

While biologics and systemics are highly effective, they work by suppressing parts of your immune system. This means they can carry an increased risk of infections. Your doctor will require screening for conditions like tuberculosis (TB) before starting and will monitor your blood work regularly.

Note on Insurance

While biologics are highly effective, insurance companies often require “step therapy”—meaning you must try and fail cheaper creams or pills before they will cover an injectable biologic.

Emergency Care: Erythrodermic Psoriasis

Severe erythrodermic flares (where the skin is red and peeling over the entire body) are medical emergencies [18]. Management focuses on rapid stabilization in a hospital setting, often using high-dose “rescue” therapies like intravenous medications or rapid-acting biologics to prevent life-threatening complications like shock or severe infection [19][2].

The goal of modern medicine is no longer just “improvement”; for most patients, achieving clear or almost clear skin is now a realistic and expected outcome of treatment [20].

Common questions in this guide

When does psoriasis require systemic treatment instead of creams?
Doctors usually recommend systemic treatments when psoriasis covers more than 10% of the body or severely affects high-impact areas like the face, hands, or genitals.
What is the difference between IL-17 and IL-23 inhibitor biologics?
IL-17 inhibitors generally work faster to clear the skin, while IL-23 inhibitors are known for their durability and often require fewer injections, such as once every three months.
What is step therapy for psoriasis medication?
Step therapy is an insurance requirement where you must first try and fail less expensive treatments, like topical creams or older oral pills, before your insurance provider will cover newer, targeted biologic injections.
Is it safe to stop using steroid creams for my psoriasis?
You should not stop using steroid creams abruptly without your dermatologist's guidance. Stopping suddenly can cause a rebound flare, making your psoriasis symptoms rapidly return and worsen.
What is an erythrodermic psoriasis flare?
Erythrodermic psoriasis is a severe, life-threatening emergency where the skin becomes intensely red and peels over the entire body. It requires immediate medical attention and rapid stabilization in a hospital setting.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my body surface area and the impact on my life, do I meet the criteria for 'moderate-to-severe' psoriasis?
  2. 2.Given my symptoms, would an IL-17 inhibitor (for speed) or an IL-23 inhibitor (for long-term durability) be a better fit?
  3. 3.If we choose an oral medication like apremilast or methotrexate, what are the specific safety risks or monitoring requirements?
  4. 4.How long should we trial my current treatment before deciding if we need to 'escalate' to a more targeted therapy?
  5. 5.Are there any biologics that you consider 'first-line' for my specific situation, rather than following a step-therapy approach?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Treatment Options for Pediatric Psoriasis.

    Madiraca D, Šitum M, Prkačin I, Ožanić Bulić S

    Acta dermatovenerologica Croatica : ADC 2016; (24(3)):175-80.

    PMID: 27663917
  2. 2

    Efficacy and safety of biologics in erythrodermic psoriasis: a systematic review and single-arm meta-analysis.

    Gao L, Shen L, Yan H, et al.

    Frontiers in immunology 2025; (16()):1714587 doi:10.3389/fimmu.2025.1714587.

    PMID: 41235248
  3. 3

    Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis.

    Kin KC, Hill D, Feldman SR

    Expert review of clinical pharmacology 2016; (9(6)):789-97 doi:10.1080/17512433.2016.1179574.

    PMID: 27089906
  4. 4

    A novel vehicle for the treatment of psoriasis.

    Dattola A, Silvestri M, Bennardo L, et al.

    Dermatologic therapy 2020; (33(1)):e13185 doi:10.1111/dth.13185.

    PMID: 31830367
  5. 5

    Tapinarof Cream 1%: First Approval.

    Keam SJ

    Drugs 2022; (82(11)):1221-1228 doi:10.1007/s40265-022-01748-6.

    PMID: 35939180
  6. 6

    Comparative evaluation of efficacy and safety of calcipotriol versus tacalcitol ointment, both in combination with NBUVB phototherapy in the treatment of stable plaque psoriasis.

    Dua I, Aggarwal K, Jain VK

    Photodermatology, photoimmunology & photomedicine 2017; (33(5)):275-281 doi:10.1111/phpp.12324.

    PMID: 28602032
  7. 7

    Comparative evaluation of efficacy and safety of calcipotriol versus calcitriol ointment, both in combination with narrow-band ultraviolet B phototherapy in the treatment of stable plaque psoriasis.

    Chakraborty D, Aggarwal K

    Photodermatology, photoimmunology & photomedicine 2023; (39(5)):512-519 doi:10.1111/phpp.12893.

    PMID: 37293775
  8. 8

    Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France.

    Tournier A, Khemis A, Maccari F, et al.

    Annales de dermatologie et de venereologie 2019; (146(2)):106-114 doi:10.1016/j.annder.2018.11.011.

    PMID: 30704943
  9. 9

    Apremilast: First Pediatric Approval.

    Blair HA

    Paediatric drugs 2025; (27(1)):119-124 doi:10.1007/s40272-024-00668-0.

    PMID: 39576565
  10. 10

    Apremilast: A Review in Psoriasis and Psoriatic Arthritis.

    Deeks ED

    Drugs 2015; (75(12)):1393-403 doi:10.1007/s40265-015-0439-1.

    PMID: 26220911
  11. 11

    Palmoplantar plaque psoriasis responsive to upadacitinib: A report of two cases.

    Choi B, Li HO, Glassman SJ

    SAGE open medical case reports 2025; (13()):2050313X251317763 doi:10.1177/2050313X251317763.

    PMID: 39897569
  12. 12

    Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.

    Armstrong AW, Read C

    JAMA 2020; (323(19)):1945-1960 doi:10.1001/jama.2020.4006.

    PMID: 32427307
  13. 13

    Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-Analysis.

    Papp KA, Vender R, Purdy K, et al.

    Dermatology and therapy 2025; (15(9)):2615-2629 doi:10.1007/s13555-025-01463-6.

    PMID: 40676461
  14. 14

    A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.

    Blauvelt A, Leonardi C, Elewski B, et al.

    The British journal of dermatology 2021; (184(6)):1047-1058 doi:10.1111/bjd.19509.

    PMID: 32880909
  15. 15

    Assessing the 5-year persistence in positive clinical response with innovative psoriasis treatments: a network meta-analysis of Psoriasis Area and Severity Index score.

    Husein-ElAhmed H, Husein-ElAhmed S

    Clinical and experimental dermatology 2024; (49(10)):1148-1155 doi:10.1093/ced/llae131.

    PMID: 38618735
  16. 16

    Efficacy and Safety of IL-17 and IL-23 Inhibitors in Elderly Patients With Plaque Psoriasis: A Real-World Study.

    Hacınecipoğlu F, Çelik G, Kartal SP

    The Journal of dermatology 2025; (52(7)):1166-1174 doi:10.1111/1346-8138.17755.

    PMID: 40285439
  17. 17

    Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).

    Papp K, Reich K, Leonardi CL, et al.

    Journal of the American Academy of Dermatology 2015; (73(1)):37-49.

    PMID: 26089047
  18. 18

    Erythrodermic Psoriasis and Staph-Infective Endocarditis-A Conundrum in Succession.

    Patel A, Venter F, Grewal K, et al.

    Journal of investigative medicine high impact case reports 2022; (10()):23247096221105243 doi:10.1177/23247096221105243.

    PMID: 35726179
  19. 19

    Erythrodermic psoriasis with early diagnostic uncertainty requiring multidisciplinary rheumatological management: A case report.

    Danagara SR, Selvarajan T, Kannekanti L, et al.

    Medicine international 2026; (6(5)):46 doi:10.3892/mi.2026.330.

    PMID: 42523983
  20. 20

    Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations.

    Gisondi P, Talamonti M, Chiricozzi A, et al.

    Dermatology and therapy 2021; (11(1)):235-252 doi:10.1007/s13555-020-00475-8.

    PMID: 33426634

This page is for informational purposes only and does not replace professional medical advice. Always consult your dermatologist to discuss the most appropriate psoriasis treatment plan for your specific symptoms.

Get notified when new evidence is published on psoriasis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.